Anti-hypertensive Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

The Anti-hypertensive Drugs market is segmented by Therapeutic Class (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Alpha Blockers, Renin Inhibitors, Calcium Channel Blockers, Other Therapeutic Classes), and Geography

Anti-hypertensive Drugs Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

4.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Certain factors that are driving the market growth include increasing prevalence of hypertension, growing initiatives by private and government organizations, and rising awareness about hypertension.

The prevalence of hypertension has observed a significant rise over the past few years. Generally, blood pressure rises and falls throughout the day. However, it can damage one’s heart and result in health problems, if it stays high for a long time. High blood pressure is called hypertension. High blood pressure is the most harmful factor when it comes to the risk of heart disease and stroke, which is the leading cause of death in the United States, as stated by the World Health Organization. According to the CDC (Centers for Disease Control and Prevention, 2017), about 75 million American adults (32%) have high blood pressure (hypertension), but only about half (54%) of people with high blood pressure have their condition under control. CDC also states that high blood pressure costs the nation USD 48.6 billion every year. This total includes the medications to treat high blood pressure, cost of health care services, and missed days of work.

Scope of the Report

Antihypertensive drugs are referred to as a class of drugs that are used in treating hypertension (high blood pressure). There are many classes of antihypertensive drugs, which have the ability to lower blood pressure by different means, and thus, prevent the complications associated with high blood pressure, including stroke and myocardial infarction.

Therapeutic Class
Diuretics
Angiotensin Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers (ARBs)
Beta Blockers
Alpha Blockers
Renin Inhibitors
Calcium Channel Blockers
Other Therapeutic Classes
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Diuretics are Expected to Hold a Significant Market Share in the Therapeutic Class

Thiazide diuretics are the cornerstone of treatment for hypertension in most patients. Hydrochlorothiazide is the most commonly used thiazide diuretic in the United States. The Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure recommends thiazide-type diuretics to be one of the preferred drug treatments for hypertension, whether used on its own or along with other antihypertensive drugs, such as calcium channel blockers. Moreover, it was also noted that more than one-third of the adults affected by hypertension were reported to take diuretics.

To understand key trends, Download Sample Report

North America Dominates the Market and is Expected to do Same during the Forecast Period

According to the AHA (American heart association), 74.9% of hypertension patients are currently undergoing treatment, and only 52.2% of patients have it under control. AHA projection shows that by 2030, about 41.4% of adults in the United States are expected to have hypertension. 

The demand for prompt and accurate diagnosis, and treatment of hypertension, identifying people predisposed to the disease, presence of technically advanced healthcare infrastructure, and management of the prognosis of the disease are some of the key market drivers of the North American anti-hypertension market.

To understand geography trends, Download Sample Report.

Competitive Landscape

The anti-hypertensive drugs market is highly competitive and consists of a number of major players. Companies, like Astrazeneca PLC, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd, Lupin Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited, and Sanofi SA, among others, hold the substantial market share in the anti-hypertensive drugs market.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Hypertension

      2. 4.2.2 Growing Initiatives by Private and Government Organizations

      3. 4.2.3 Rising Awareness about Hypertension

    3. 4.3 Market Restraints

      1. 4.3.1 Multiple Major Drug Patent Expiration

      2. 4.3.2 Side-effects of Treatment Options

      3. 4.3.3 Rise in Non-pharmacological Therapy

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Therapeutic Class

      1. 5.1.1 Diuretics

      2. 5.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors

      3. 5.1.3 Angiotensin Receptor Blockers (ARBs)

      4. 5.1.4 Beta Blockers

      5. 5.1.5 Alpha Blockers

      6. 5.1.6 Renin Inhibitors

      7. 5.1.7 Calcium Channel Blockers

      8. 5.1.8 Other Therapeutic Classes

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East & Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East & Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Astrazeneca

      2. 6.1.2 Boehringer Ingelheim

      3. 6.1.3 Daiichi Sankyo Company Limited

      4. 6.1.4 Johnson & Johnson Ltd

      5. 6.1.5 Lupin Limited

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Novartis International AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Ranbaxy Laboratories Limited

      10. 6.1.10 Sanofi SA

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports